Table 6.11Evidence profile for trihexyphenidyl compared with placebo in children with spasticity of different severities; tone assessment

Number of studiesNumber of participantsEffectQuality
TrihexyphenidylPlaceboRelative

(95% CI)
Absolute

(95% CI)
Mean BADS score (better indicated by lower values)
1 study (Rice 2008)16a16b--cLow

BADS Barry–Albright Dystonia Scale, CI confidence interval

a

Baseline mean BAD score: 18.4 (15.5 to 21.2). Final score 18.3 (14.8 to 21.8)

b

Baseline mean BAD score: 18.4 (15.5 to 21.2). Final score 16.9 (13.4 to 20.4)

c

Reported mean difference = 0.9 (-2.2 to 3.9)

See the complete GRADE Table K.6.11 which accompanies this abbreviated version.

From: 6, Oral drugs

Cover of Spasticity in Children and Young People with Non-Progressive Brain Disorders
Spasticity in Children and Young People with Non-Progressive Brain Disorders: Management of Spasticity and Co-Existing Motor Disorders and Their Early Musculoskeletal Complications.
NICE Clinical Guidelines, No. 145.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2012 Jul.
Copyright © 2012, National Collaborating Centre for Women's and Children's Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.